TrialsgrambetaRCTs are beautiful

UKPDS 34

1998

UK Prospective Diabetes Study 34

In 753 overweight patients with newly diagnosed type 2 diabetes, intensive control with metformin reduced diabetes-related endpoints and all-cause mortality compared with conventional therapy.

Result

Primary endpoint: Any diabetes-related endpoint

Any diabetes endpoint −32 % (p=0.002); all-cause mortality −36 % (p=0.011); MI −39 % (p=0.01).

Original publication
Subtopic
Metformin
Design
RCT, median 10.7 yr follow-up
Relevance
Practice-defining: a trial the field needs to know.
Source
UKPDS Group. Lancet. 1998;352(9131):854-865.doi 10.1016/S0140-6736(98)07037-8

Discussion & critique

Established metformin as first-line therapy in overweight T2DM, a position it still holds.

Discussed in podcasts